Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2393-2398

  Reid, Joel M ^a   Stevens, David C ^a   Rubin, Joseph ^a   Ames, Matthew M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL(TRIAZEN 1 YL)IMIDAZOLE 4 CARBOXIMIDE; DRUG METABOLITE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HYDROLYSIS; DRUG POTENCY; DRUG UPTAKE; DRUG URINE LEVEL; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DACARBAZINE; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; NEOPLASMS; REGRESSION ANALYSIS;

EID: 0031426782     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L., Stone, R., Baig, G., Goddard, C., Gibson, N. W., Slack, J. A., Newton, C., Lunt, E., Fizames, C., and Lavelle, F. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res., 47: 5846-5852, 1987.
2. Tsang, L. L. H., Quarterman, C. P., Gescher, A., and Slack, J. A. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother. Pharmacol., 27: 342-346, 1991.
3. Newlands, E. S., Blackledge, G. R. P., Slack, J. A., Rustin, G. J. S., Smith, D. B., Stuart, N. S. A., Quarterman, C. P., Hoffman, R., Stevens, M. F. G., Brampton, M. H., and Gibson, A. C. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer, 65: 287-291, 1992.
4. Bleehen, N. M., Newlands, E. S., Lee, S. M., Thatcher, N., Selby, P., Calvert, A. H., Rustin, G. J. S., Brampton, M., and Stevens, M. F. G. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 13: 910-913, 1995.
5. O'Reilly, S. M., Newlands, E. S., Glaser, M. G., Brampton, M., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Kennard, C., Colquhoun, I. R., Lewis, P., and Stevens, M. F. G. Temozolomide. A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer, 29A: 940-942, 1993.
6. Mizuno, N. S., Decker, R. W., and Zakis, B. Effects of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (NSC-407347), an alkylating agent derived from 5-(3,3-dimethyl-1-trizeno)imidazole-4-carboxamide (NSC-45388). Biochem. Pharmacol., 24: 615-619, 1975.
7. 6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann. Oncol., 6: 389-393, 1995.
8. 6-alkylguanine-DNA alkyl-transferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer, 67: 1299-1302, 1993.
9. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br. J. Cancer, 69: 452-456, 1994.
10. 6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol., 32: 59-63, 1993.
11. 6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp. Hematol., 23: 112-116, 1995.
12. 6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anti-Cancer Drugs, 3: 401-405, 1992.
13. Dhodapkar, M., Rubin, J., Reid, J., Burch, P. A., Pitot, H. C., Buckner, J. C., Ames, M., and Suman, V. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin. Cancer Res., 3: 1093-1100, 1997.
14. Tsang, L. L. H., Farmer, P. B., Gescher, A., and Slack, J. A. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother. Pharmacol., 26: 429-436, 1990.
15. Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., and Slack, J. A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 33: 9045-9051, 1994.